
PMC:2944646 / 39250-39554
Annnotations
TEST0
{"project":"TEST0","denotations":[{"id":"20877425-62-70-198991","span":{"begin":62,"end":66},"obj":"[\"9266161\"]"},{"id":"20877425-88-96-198992","span":{"begin":88,"end":92},"obj":"[\"19850449\"]"},{"id":"20877425-228-236-198993","span":{"begin":246,"end":250},"obj":"[\"8914096\"]"},{"id":"20877425-228-236-198994","span":{"begin":271,"end":275},"obj":"[\"10599034\"]"}],"text":"Even in myoclonus as in movement disorders (Hanna and Bhatia, 1997; Waldbaum and Patel, 2010), mitochondrial dysfunction seems to be part of the pathophysiological basis and might be the target of piracetam's therapeutical benefit (Ikeda et al., 1996; Karacostas et al., 1999; Wolters and Benecke, 2009)."}
0_colil
{"project":"0_colil","denotations":[{"id":"20877425-9266161-198991","span":{"begin":62,"end":66},"obj":"9266161"},{"id":"20877425-19850449-198992","span":{"begin":88,"end":92},"obj":"19850449"},{"id":"20877425-8914096-198993","span":{"begin":246,"end":250},"obj":"8914096"},{"id":"20877425-10599034-198994","span":{"begin":271,"end":275},"obj":"10599034"}],"text":"Even in myoclonus as in movement disorders (Hanna and Bhatia, 1997; Waldbaum and Patel, 2010), mitochondrial dysfunction seems to be part of the pathophysiological basis and might be the target of piracetam's therapeutical benefit (Ikeda et al., 1996; Karacostas et al., 1999; Wolters and Benecke, 2009)."}
2_test
{"project":"2_test","denotations":[{"id":"20877425-9266161-38148084","span":{"begin":62,"end":66},"obj":"9266161"},{"id":"20877425-19850449-38148085","span":{"begin":88,"end":92},"obj":"19850449"},{"id":"20877425-8914096-38148086","span":{"begin":246,"end":250},"obj":"8914096"},{"id":"20877425-10599034-38148087","span":{"begin":271,"end":275},"obj":"10599034"}],"text":"Even in myoclonus as in movement disorders (Hanna and Bhatia, 1997; Waldbaum and Patel, 2010), mitochondrial dysfunction seems to be part of the pathophysiological basis and might be the target of piracetam's therapeutical benefit (Ikeda et al., 1996; Karacostas et al., 1999; Wolters and Benecke, 2009)."}